Revenue
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Plc (HEMO)
Price£5.20Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 | £0 | £0 |
| Operating expenses | £3.7M | £4.4M | £3.9M | £3.3M | N/A | N/A |
| Operating income | −£4.7M | £5.4M | £6.5M | −£4.0M | −£2.7M | −£2.2M |
| EBITDA | −£8.9M | £6.0M | £7.1M | −£3.4M | −£2.6M | −£2.0M |
| Net income | −£9.8M | −£5.6M | −£6.7M | −£4.0M | −£5.1M | −£2.1M |
| Basic EPSper basic share | -£1.71 | -£0.02 | -£0.02 | £0.01 | £0.01 | £0.01 |
| Diluted EPSper diluted share | -£1.71 | -£0.02 | -£0.02 | £0.01 | £0.01 | £0.01 |
Owners
Reported major voting-rights holders
7.76%of voting rights
David John SmithNotified Jan 6, 2026
View holders
| Holder | Voting rights |
|---|---|
| 7.76%Jan 6, 2026 · 468.92K votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: FCA voting-rights notice ↗Updated Oct 21, 2026
Community posts
Hemogenyx loss widens on non-cash options charge despite lower underlying spending
Hemogenyx Pharmaceuticals ($HEMO) reported a first-half pretax loss of £6.56 million, widening from £5.01 million. Reported operating costs increased to £6.48 million, but the company attributed most of the rise to a £5.54 million non-cash ...
